

=====

Sequence Listing was accepted.

See attached Validation Report.

If you need help call the Patent Electronic Business Center at (866)
217-9197 (toll free).

Reviewer: Durreshwar Anjum

Timestamp: [year=2009; month=4; day=14; hr=12; min=41; sec=58; ms=275;]

=====

Application No: 10551482 Version No: 2.0

Input Set:

Output Set:

Started: 2009-03-19 20:37:50.215
Finished: 2009-03-19 20:37:51.188
Elapsed: 0 hr(s) 0 min(s) 0 sec(s) 973 ms
Total Warnings: 5
Total Errors: 6
No. of SeqIDs Defined: 6
Actual SeqID Count: 6

Error code	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (1)
E 257	Invalid sequence data feature in <221> in SEQ ID (1)
E 257	Invalid sequence data feature in <221> in SEQ ID (1)
W 213	Artificial or Unknown found in <213> in SEQ ID (2)
W 213	Artificial or Unknown found in <213> in SEQ ID (3)
W 213	Artificial or Unknown found in <213> in SEQ ID (4)
E 257	Invalid sequence data feature in <221> in SEQ ID (4)
E 257	Invalid sequence data feature in <221> in SEQ ID (4)
E 257	Invalid sequence data feature in <221> in SEQ ID (4)
W 213	Artificial or Unknown found in <213> in SEQ ID (5)
E 257	Invalid sequence data feature in <221> in SEQ ID (5)

SEQUENCE LISTING

<110> Weston-Davies, Wynne

<120> Histamine binding Compounds for Treatment Method for Disease Conditions
Mediated by Neutrophils

<130> 2488-1-011

<140> 10551482

<141> 2009-03-19

<150> PCT/GB2004/001428

<151> 2004-04-01

<150> GB0307544.7

<151> 2003-04-01

<160> 6

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic Peptide

<220>

<221> Xaa

<222> (1)..(1)

<223> Xaa can be Asp or Glu

<220>

<221> Xaa

<222> (4)..(4)

<223> Xaa can be Lys or Arg

<400> 1

Xaa Ala Trp Xaa

1

<210> 2

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic Peptide

<400> 2

Asp Ala Trp Lys

1

<210> 3
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Peptide

<400> 3
Gln Asp Ala Trp Lys
1 5

<210> 4
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Peptide

<220>
<221> Xaa
<222> (1)..(1)
<223> Xaa can be Tyr or Cys

<220>
<221> Xaa
<222> (2)..(2)
<223> Xaa can be Glu or Asp

<220>
<221> Xaa
<222> (3)..(3)
<223> Xaa can be Leu or Ile or Phe

<400> 4
Xaa Xaa Xaa Trp
1

<210> 5
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Peptide

<220>
<221> Xaa
<222> (1)..(1)
<223> Xaa can be Tyr or Cys

<400> 5

Xaa Glu Leu Trp

1

<210> 6

<211> 190

<212> PRT

<213> *Rhipicephalus appendiculatus*

<400> 6

Met Lys Leu Leu Ile Leu Ser Leu Ala Leu Val Leu Ala Leu Ser Gln

1 5 10 15

Val Lys Gly Asn Gln Pro Asp Trp Ala Asp Glu Ala Ala Asn Gly Ala

20 25 30

His Gln Asp Ala Trp Lys Ser Leu Lys Ala Asp Val Glu Asn Val Tyr

35 40 45

Tyr Met Val Lys Ala Thr Tyr Lys Asn Asp Pro Val Trp Gly Asn Asp

50 55 60

Phe Thr Cys Val Gly Val Met Ala Asn Asp Val Asn Glu Asp Glu Lys

65 70 75 80

Ser Ile Gln Ala Glu Phe Leu Phe Met Asn Asn Ala Asp Thr Asn Met

85 90 95

Gln Phe Ala Thr Glu Lys Val Thr Ala Val Lys Met Tyr Gly Tyr Asn

100 105 110

Arg Glu Asn Ala Phe Arg Tyr Glu Thr Glu Asp Gly Gln Val Phe Thr

115 120 125

Asp Val Ile Ala Tyr Ser Asp Asp Asn Cys Asp Val Ile Tyr Val Pro

130 135 140

Gly Thr Asp Gly Asn Glu Glu Gly Tyr Glu Leu Trp Thr Thr Asp Tyr

145 150 155 160

Asp Asn Ile Pro Ala Asn Cys Leu Asn Lys Phe Asn Glu Tyr Ala Val

165 170 175

Gly Arg Glu Thr Arg Asp Val Phe Thr Ser Ala Cys Leu Glu

180 185 190